Patents by Inventor Robert D. Larsen
Robert D. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11980911Abstract: A sprayer includes a spray gun and a hopper. An air source provides compressed air to the sprayer to both eject fluid from the spray gun as a spray and to pressurize the hopper. The spray gun includes passages for providing compressed air to the nozzle for spraying and to the hopper for pressurizing the hopper. The spray gun further includes a relief valve for venting pressurized air from the hopper. The hopper receives the compressed air through a port in the hopper, and the compressed air assists the flow of material out of the hopper and into the spray gun.Type: GrantFiled: March 23, 2023Date of Patent: May 14, 2024Assignee: Graco Minnesota Inc.Inventors: Steven D. Becker, David M. Larsen, Steve J. Wrobel, Mark D. Shultz, Robert J. Gundersen
-
Patent number: 7264485Abstract: The present invention relates to electrical connectors, and, in particular, to power connectors and to improved contact structures and methods related thereto.Type: GrantFiled: September 7, 2006Date of Patent: September 4, 2007Assignee: Winchester Electronics CorporationInventors: Robert D. Larsen, Lee M. Drozdenko
-
Patent number: 7160122Abstract: The present invention relates to electrical connectors, and, in particular, to power connectors and to improved contact structures and methods related thereto.Type: GrantFiled: October 19, 2005Date of Patent: January 9, 2007Assignee: Winchester Electronics CorporationInventors: Robert D. Larsen, Lee M. Drozdenko
-
Publication number: 20040023977Abstract: The present invention relates to a process for preparing substituted thiazolyl-amino pyrimidinyl piperazines, which are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.Type: ApplicationFiled: July 14, 2003Publication date: February 5, 2004Inventors: Robert D. Larsen, Anthony On-Ping King
-
Publication number: 20030134307Abstract: This invention provides methods for performing combined asymmetric amplification (e.g., asymmetric PCR amplification) and detection of nucleic acid targets using molecular beacons to detect the products. Methods using a polymerase having reduced or eliminated 5′ to 3′ nuclease activity are provided, as are methods using nuclease-resistant molecular beacons. Asymmetric amplifications using nuclease-free polymerase or nuclease-resistant molecular beacons provide dramatic improvements in signal intensity detected as a result of molecular beacon binding to a target nucleic acid, e.g., during asymmetric PCR. Attendant compositions, systems, devices and kits are also features of the invention.Type: ApplicationFiled: October 25, 2002Publication date: July 17, 2003Applicant: Gorilla Genomics, Inc.Inventors: Kenneth B. Beckman, Robert D. Larsen, Kathleen Y. Lee
-
Patent number: 6372911Abstract: A process for preparing a &bgr;-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalyst, a co-oxidant selected from a halohydantoin, a haloisocyanuric acid, and an alkali metal salt of a haloisocyanuric acid, and optionally an asymmetric ligand, to form a reaction mixture containing the &bgr;-hydroxy carbamate product. The process optionally further comprises treating the &bgr;-hydroxy carbamate product with additional base to form an oxazolidinone. The oxazolidinones are useful as chiral auxiliary agents and as intermediates for the formation of pharmaceutically active substances such as alpha 1 a adrenergic receptor antagonists. A process for preparing nitrogen-functionalized derivatives of the oxazolidinones is also disclosed.Type: GrantFiled: January 13, 2000Date of Patent: April 16, 2002Assignee: Merck & Co., Inc.Inventors: Nancy Barta, Robert D. Larsen, Daniel R. Sidler, Steven A. Weissman
-
Patent number: 6369275Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: November 17, 2000Date of Patent: April 9, 2002Assignee: Merck & Co., Inc.Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
-
Patent number: 6320049Abstract: This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.Type: GrantFiled: May 2, 2000Date of Patent: November 20, 2001Assignee: Merck & Co., Inc.Inventors: Daniel R. Sidler, Robert D. Larsen, Wenjie Li
-
Patent number: 6281391Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.Type: GrantFiled: October 27, 1999Date of Patent: August 28, 2001Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
-
Patent number: 6252116Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: January 21, 2000Date of Patent: June 26, 2001Assignee: Merck & Co., Inc.Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
-
Patent number: 6204387Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: March 23, 2000Date of Patent: March 20, 2001Assignee: Merck & Co., Inc.Inventors: Ian W. Davies, Linda Gerena, Michel Journet, Robert D. Larsen, Philip J. Pye, Kai Rossen
-
Patent number: 6140515Abstract: Described is a process of preparing 3-aryl, 4-aryloxy furan-5-ones which are useful as inhibitors of cyclooxygenase-2 (COX-2). Such compounds are useful as anti-inflammatory agents. The process is directed to an asymmetric synthesis which involves: a trisubstituted styrene derivative preparation via Horner-Wadsworth-Emmons reaction and subsequent one pot trifluoromethylation of the allylic alcohol; preparation of the .alpha.-hydroxyl ketone using Sharpless asymmetric dihydroxylation and Swern oxidation; the esterification of the .alpha.-hydroxyl ketone with the phenoxy acetic acid; and the Dieckman condensation of the resulting ester.Type: GrantFiled: September 15, 1998Date of Patent: October 31, 2000Assignee: Merck & Co., Inc.Inventors: Cheng Y. Chen, Lushi Tan, Robert D. Larsen
-
Patent number: 6127545Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: September 18, 1998Date of Patent: October 3, 2000Assignee: Merck & Co., Inc.Inventors: Philip J. Pye, Kai Rossen, Ashok Maliakal, Ralph P. Volante, Jess Sager, Jean-Francois Marcoux, Ian Davies, Edward G. Corley, Daniel Richard Sidler, Robert D. Larsen
-
Patent number: 6051707Abstract: The present invention is concerned with a novel linear process for the preparation of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl)-ethoxy)-4-(5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S) -(4-fluorophenyl)-morpholine which is a potent and selective substance P (or neurokinin-1) receptor antagonist usefull as a therapeutic agent.Type: GrantFiled: October 28, 1999Date of Patent: April 18, 2000Assignee: Merck & Co., Inc.Inventors: Dongwei Cai, Michel Journet, Robert D. Larsen
-
Patent number: 6040450Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: September 15, 1998Date of Patent: March 21, 2000Assignee: Merck & Co., Inc.Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
-
Patent number: 6040319Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.Type: GrantFiled: April 23, 1999Date of Patent: March 21, 2000Assignee: Merck & Co., Inc.Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
-
Patent number: 5877329Abstract: Indoles of structural formula (III): ##STR1## are synthesized by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline and an alkyl ketone derivative. The process is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a facile leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride.Type: GrantFiled: August 7, 1997Date of Patent: March 2, 1999Assignee: Merck & Co., Inc.Inventors: Cheng-Yi Chen, Robert D. Larsen
-
Patent number: 5834502Abstract: The bisulfate salt of N,N-dimethyl-2-?5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl!ethylamine is a selective agonist of 5-HT.sub.1 -like receptors and is useful in the treatment of migraine and associated disorders.Type: GrantFiled: July 11, 1996Date of Patent: November 10, 1998Assignee: Merck & Co., Inc.Inventors: Chen Y. Cheng, James A. McCauley, Jennifer L. Vandrilla, Thomas R. Verhoeven, Robert D. Larsen
-
Patent number: 5811551Abstract: We have found that indoles of structural formula (III): ##STR1## can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo- or 2-trifluoromethylsulfonyl-aniline and a cyclic ketone derivative. The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride.Type: GrantFiled: August 7, 1997Date of Patent: September 22, 1998Assignee: Merck & Co., Inc.Inventors: Cheng-Yi Chen, Robert D. Larsen
-
Patent number: 5808064Abstract: We have found that 2-unsubstituted indoles of structural formula (IV) can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline (I) and an acyl silane derivative (II), followed by deprotection of the silyl protecting groups. ##STR1## The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride. When applied to 5-triazolyl substituted indoles, the present process also eliminates the tendency of triazolyl polymerization in the Fischer indole synthesis.Type: GrantFiled: August 7, 1997Date of Patent: September 15, 1998Assignee: Merck & Co., Inc.Inventors: Cheng-Yi Chen, Robert D. Larsen